BofA analyst Craig Bijou lowered the firm’s price target on GE HealthCare to $86 from $94 and keeps a Neutral rating on the shares. A “surprise” Q1 revenue and EPS miss weighed heavily on shares and GE HealthCare will “likely be a show me story from here,” says the firm, which adds that the company “set a relatively low bar for revenue growth in Q2.” The firm thinks the Q1 miss and steeper second half ramp add incremental risk, BofA noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare backs FY24 adjusted EPS view $4.20-$4.35, consensus $4.30
- GE HealthCare reports Q1 adjusted EPS 90c, consensus 91c
- Philips upgraded to Neutral from Underweight at JPMorgan
- FDA clears GE HealthCare’s Portrait VSM for connected patient monitoring
- GE Healthcare CEO Resigns, Successor Search Begins